These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 6131248)

  • 1. Epoprostenol (prostacyclin) infusion in patients with Raynaud's syndrome.
    Kahan A; Weber S; Amor B; Menkes CJ
    Lancet; 1983 Mar; 1(8323):538. PubMed ID: 6131248
    [No Abstract]   [Full Text] [Related]  

  • 2. Intermittent epoprostenol (prostacyclin) infusion in patients with Raynaud's syndrome. A double-blind controlled trial.
    Belch JJ; Newman P; Drury JK; McKenzie F; Capell H; Leiberman P; Forbes CD; Prentice CR
    Lancet; 1983 Feb; 1(8320):313-5. PubMed ID: 6130329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of Raynaud's phenomenon by intravenous infusion of prostacyclin (PGI2).
    Dowd PM; Martin MF; Cooke ED; Bowcock SA; Jones R; Dieppe PA; Kirby JD
    Br J Dermatol; 1982 Jan; 106(1):81-9. PubMed ID: 7037038
    [No Abstract]   [Full Text] [Related]  

  • 4. Prostacyclin and the fibrinolytic system in ischemic vascular disease.
    Szczeklik A; Kopec M; Sladek K; Musial J; Chmielewska J; Teisseyre E; Dudek-Wojciechowska G; Palester-Chlebowczyk M
    Thromb Res; 1983 Mar; 29(6):655-60. PubMed ID: 6344316
    [No Abstract]   [Full Text] [Related]  

  • 5. Raynaud's disease and prostacyclin.
    Kennerly D
    Ann Intern Med; 1983 Feb; 98(2):258. PubMed ID: 6337542
    [No Abstract]   [Full Text] [Related]  

  • 6. Epoprostenol in patients with Raynaud's disease.
    Fitscha P; Kaliman J; Weidinger F; Sinzinger H; O'Grady J
    Prostaglandins Leukot Essent Fatty Acids; 1988 Jul; 33(1):23-7. PubMed ID: 3141936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Infusion of prostacyclin (epoprostenol).
    Mikhailidis DP; Mikhailidis AM; Barradas MA; Dandona P
    Lancet; 1982 Oct; 2(8301):767. PubMed ID: 6125834
    [No Abstract]   [Full Text] [Related]  

  • 8. Successful treatment of Raynaud's Syndrome with prostacyclin.
    Belch JJ; Newman P; Drury JK; Capell H; Leiberman P; James WB; Forbes CD; Prentice CR
    Thromb Haemost; 1981 Jun; 45(3):255-6. PubMed ID: 7025341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolonged remission in Raynaud's phenomenon after prostacyclin infusion.
    Bellucci S; Kedra AW; Courmelle JM; Maclouf J; Boizard B; Dosquet-Bernard C; Tobelem G; Caen JP
    Scand J Rheumatol; 1986; 15(4):392-8. PubMed ID: 3547631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence for the Use of Epoprostenol to Treat Raynaud's Phenomenon With or Without Digital Ulcers.
    Cruz JE; Ward A; Anthony S; Chang S; Bae HB; Hermes-DeSantis ER
    Ann Pharmacother; 2016 Dec; 50(12):1060-1067. PubMed ID: 27465880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Digital necrosis in Raynaud's phenomenon revealing a testicular seminoma. Value of prostacyclin].
    Taillan B; Ferrari E; Castanet J; Campagni JP; Garnier G; Fuzibet JG; Benchimol D; Dujardin P
    Presse Med; 1992 Jun; 21(23):1070-1. PubMed ID: 1387938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study.
    Rademaker M; Cooke ED; Almond NE; Beacham JA; Smith RE; Mant TG; Kirby JD
    BMJ; 1989 Mar; 298(6673):561-4. PubMed ID: 2467711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Raynaud's disease.
    Burns EC; Dunger DB; Dillon MJ
    Arch Dis Child; 1985 Jun; 60(6):537-41. PubMed ID: 3160308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New prospects for the treatment of Raynaud's phenomenon using a serotoninergic S2 receptor antagonist (ketanserin) and stable derivatives of prostacyclin.
    Pola P; Tondi P; Serricchio M; Favuzzi A; Gerardino L
    Angiology; 1993 Feb; 44(2):123-8. PubMed ID: 8434805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Trial treatment of severe Raynaud's phenomenon with prostacyclin (PGI2)].
    Cabane J; Boue F; Godeau P; Lecompte T; Charpentier MC; Samama M; Nebout T
    Rev Med Interne; 1985 Dec; 6(5):581-9. PubMed ID: 3914023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment of severe Raynaud syndrome in scleroderma or thromboangiitis obliterans with prostacyclin (prostaglandin I2)].
    Rüthlein HJ; Riegger G; Auer IO
    Z Rheumatol; 1991; 50(1):16-20. PubMed ID: 2058317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [1st intravenous administration of prostacyclin to man].
    Szczeklik A; Gryglewski R; Nizankowski R; Musiał J; Serwońska M; Pietoń R; Mruk J
    Pol Tyg Lek; 1978 Sep; 33(36):1405-8. PubMed ID: 360190
    [No Abstract]   [Full Text] [Related]  

  • 18. [Treatment of Raynaud's phenomenon in scleroderma with a new stable prostacyclin derivative].
    Keller J; Kaltenecker A; Schricker KT; Krais T; Schönberger A; Gevatter M; Hornstein OP
    Dtsch Med Wochenschr; 1984 Sep; 109(38):1433-8. PubMed ID: 6383760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute hemodynamic effects of prostacyclin infusion in severe or malignant hypertension.
    Chaignon M; Tannieres-Ruffie ML; Lucsko M; Guedon J
    Eur Heart J; 1982 Oct; 3 Suppl C():39-43. PubMed ID: 6756922
    [No Abstract]   [Full Text] [Related]  

  • 20. [Prostacyclin in ischemic stroke].
    Nowak S; Gryglewski R; Kostka-Trabkowa E; Bieroń K; Dembińska-Kieć A; Kuśmiderski J; Błaszczyk B; Olczyk E; Markowska E; Basista M
    Przegl Lek; 1983; 40(3):315-22. PubMed ID: 6191364
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.